These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 791234)
101. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Klöcker N; Hanschke W; Toussaint S; Verse T Eur J Pharm Sci; 2001 May; 13(2):227-32. PubMed ID: 11297908 [TBL] [Abstract][Full Text] [Related]
103. Effects of transdermal scopolamine upon psychological test performance at sea. Parrott AC; Jones R Eur J Clin Pharmacol; 1985; 28(4):419-23. PubMed ID: 4029247 [TBL] [Abstract][Full Text] [Related]
104. The prevention of seasickness with hyoscine, benadryl, and phenergan. GLASER EM; HERVEY GR Lancet; 1951 Oct; 2(6687):749-53. PubMed ID: 14874498 [No Abstract] [Full Text] [Related]
105. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. Nuotto E Eur J Clin Pharmacol; 1983; 24(5):603-9. PubMed ID: 6873137 [TBL] [Abstract][Full Text] [Related]
106. Prevention of motion sickness in flight maneuvers, aided by transfer of adaptation effects acquired in the laboratory: ten consecutive referrals. Graybiel A; Knepton J Aviat Space Environ Med; 1978 Jul; 49(7):914-9. PubMed ID: 666686 [TBL] [Abstract][Full Text] [Related]
107. Transdermal scopolamine for peripheral vertigo (a double-blind study). Rahko T; Karma P J Laryngol Otol; 1985 Jul; 99(7):653-6. PubMed ID: 3894551 [TBL] [Abstract][Full Text] [Related]
108. [Aminalon as an agent for the prevention of motion sickness]. Lapaev EV; Voinova II; Vorob'ev OA; Barmicheva NM Zh Ushn Nos Gorl Bolezn; 1978; (5):35-9. PubMed ID: 360685 [No Abstract] [Full Text] [Related]
109. [Antimotion sickness effects of ginsenosides combined with dexamethasone in rats]. Jia L; Wang WY; Zhou LM; Mo FF; Li M Zhong Xi Yi Jie He Xue Bao; 2010 Apr; 8(4):358-62. PubMed ID: 20388477 [TBL] [Abstract][Full Text] [Related]
110. Nuclear medicine evaluation of motion sickness and medications on gastric emptying time. Wood MJ; Wood CD; Manno JE; Manno BR; Redetzki HM Aviat Space Environ Med; 1987 Nov; 58(11):1112-4. PubMed ID: 3318799 [TBL] [Abstract][Full Text] [Related]
111. Fixed dilated pupil in the long distance traveller. Dunlop IS Med J Aust; 1995 Jan; 162(1):56. PubMed ID: 7845307 [No Abstract] [Full Text] [Related]
112. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Al-Ghananeem AM; Malkawi AH; Crooks PA Drug Dev Ind Pharm; 2007 May; 33(5):577-82. PubMed ID: 17520450 [TBL] [Abstract][Full Text] [Related]
113. Intramuscular hyoscine in control of motion sickness. Brand JJ; Whittingham P Lancet; 1970 Aug; 2(7666):232-4. PubMed ID: 4193688 [No Abstract] [Full Text] [Related]
114. Effects of anti-motion sickness drugs on motion sickness in rats. Morita M; Takeda N; Kubo T; Yamatodani A; Wada H; Matsunaga T ORL J Otorhinolaryngol Relat Spec; 1988; 50(5):330-3. PubMed ID: 3186231 [TBL] [Abstract][Full Text] [Related]
117. Further experiments on the prevention of motion sickness. GLASER EM; HERVEY GR Lancet; 1952 Mar; 1(6706):490-2. PubMed ID: 14898786 [No Abstract] [Full Text] [Related]
118. [Effect of pharmacological agents to prevent the motion sickness syndrome on the cardiovascular system in simulating the early period of adaptation to weightlessness]. Il'ina SL; Sabaev VV; Shashkov VS; Karsanova SK Farmakol Toksikol; 1986; 49(3):90-5. PubMed ID: 3720942 [TBL] [Abstract][Full Text] [Related]